Skip to main content
Hybrigenics SA logo

Hybrigenics SA — Investor Relations & Filings

Ticker · ALHYG ISIN · FR0004153930 LEI · 9695003KQD0XMJYDX764 PA Professional, scientific and technical activities
Open in API
Filings indexed 145 across all filing types
Latest filing 2022-06-27 Regulatory Filings
Country FR France
Listing PA ALHYG

About Hybrigenics SA

https://www.hybrigenics-services.com/

Hybrigenics Services is a specialized provider of technologies for studying molecular interactions. Its core offering is the ULTImate Y2H™ platform, a comprehensive Yeast Two-Hybrid system used to discover protein-protein interactions, as well as interactions with DNA, RNA, and small molecules. This technology is applied to drug discovery for target deconvolution and identifying molecular glues. A second key service is the Hybribody platform, which leverages a proprietary synthetic library for the custom selection, validation, and optimization of single-domain antibodies (VHHs/Nanobodies). The company serves clients in fundamental research, pharmaceutical R&D, and agroscience.

Recent filings

Filing Released Lang Actions
Stemcis obtient l'autorisation de la FDA pour la commercialisation de ses dispositifs médicaux aux Etats-Unis
Regulatory Filings Classification · 100% confidence The document is a press release from Hybrigenics SA announcing that its subsidiary, Stemcis, received FDA clearance (authorization) to market its medical devices in the United States. This announcement details a significant operational and regulatory milestone, specifically related to product approval and market expansion. This type of announcement, which is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific capital/financing event (CAP), falls best under a general regulatory or corporate announcement. Since it is a specific, non-financial regulatory event (FDA clearance), and it doesn't fit the definitions for AGM-R, AR, MANG, CT, DVA, DLST, DIRS, SR, FS, CGR, IRAT, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS, the most appropriate general category for a significant, non-standard regulatory/operational update is 'Regulatory Filings' (RNS), as it is a formal announcement of a regulatory outcome.
2022-06-27 French
Accord de distribution aux Etats-Unis
Regulatory Filings Classification · 87% confidence The document announces a distribution agreement between Stemcis (a subsidiary of Hybrigenics SA) and a US company, Overnia, for the exclusive sale and marketing of medical devices in the US. This concerns a strategic business development, partnership, and expansion into a new market. This type of announcement, detailing a significant business transaction or strategic move that is not a standard financial report (like 10-K, ER, or IR), best fits the category for M&A Activity (TAR) if it were an acquisition/merger, or more generally, a Regulatory Filing (RNS) if it doesn't fit elsewhere. Since it is a specific business development announcement (a distribution agreement) that doesn't map directly to financing (CAP), management change (MANG), or legal issues (LTR), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), as it is a material event announcement. However, given the options, this is a strategic business development announcement. It is not a merger/takeover (TAR), but a distribution agreement. It is not a capital change (CAP) or management change (MANG). It is a significant corporate event announcement. RNS is the best fit as a general regulatory announcement for material, non-standard news.
2022-06-07 French
Stemcis conclut un partenariat stratégique pour la formation au protocole d'arthro-thérapie MYFILL - Objectif : former une centaine de chirurgiens d'ici fin 2023
Regulatory Filings Classification · 100% confidence The document announces a strategic partnership between Stemcis (a subsidiary of Hybrigenics SA) and Dr. Yves Depaepe regarding the training protocol for the MYFILL arthrotherapy kit. It details the medical context, the solution provided by MYFILL, and the goal to train surgeons. This type of announcement, focusing on a specific business development, partnership, or strategic move that is not a standard financial report (like 10-K, ER, or IR), fits best under a general regulatory or corporate announcement category. Since there is no specific category for 'Partnership Announcement' or 'Business Development,' and the document is a press release format announcing a corporate action, it falls under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate news releases that don't fit the highly specific financial or governance codes. The document length is short (2969 chars), suggesting it is a release rather than a comprehensive report.
2022-05-31 French
Résultats annuels 2021
Earnings Release Classification · 95% confidence The document is a press release titled 'Résultats annuels 2021' (Annual Results 2021) for Hybrigenics SA. It provides a summary of financial performance, including income statement highlights and balance sheet data for the fiscal year 2021. While it references the full annual report being available on the website, the document itself contains substantive financial data and management commentary on the results and outlook, which aligns with the definition of an Earnings Release (ER) or a summary of annual results. Given the focus on the initial announcement of annual financial highlights, 'ER' is the most appropriate classification. FY 2021
2022-04-29 French
Obtention du marquage CE et lancement de la commercialisation du nouveau dispositif médical Macrofill vacuum
Regulatory Filings Classification · 100% confidence The document announces a significant business development: Hybrigenics SA has obtained CE marking and launched the commercialization of a new medical device, Macrofill vacuum. This is a specific operational update concerning product approval and market entry, not a standard periodic financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). It details a strategic business achievement. Since there is no specific category for 'Product Launch/Regulatory Approval Announcement' that fits perfectly, and it is a material, non-financial announcement, it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard corporate news. Given the content is a direct announcement of a business event rather than a formal regulatory filing document itself, RNS is the most appropriate general category among the choices provided.
2022-04-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital au 31 mars 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital au 31 mars 2022" (Information relative to the total number of voting rights and shares comprising the capital as of March 31, 2022). It explicitly states that the company is publishing this information in accordance with French commercial code (L. 233-8 II) and AMF regulations (223-16). This type of mandatory disclosure, detailing the total number of shares and voting rights, is typically classified as a regulatory filing or a specific announcement related to capital structure/voting rights. Reviewing the definitions, this content most closely aligns with a notification regarding the capital structure or voting rights, which often falls under general regulatory announcements if a more specific code isn't available. However, since it details the total number of shares and voting rights, it is a fundamental disclosure about the company's capital structure. While 'SHA' (Share Issue/Capital Change) might seem close, this is a periodic reporting of the *current* count, not an announcement of a change event. Given the context of mandatory regulatory disclosure of voting rights and share count, and the lack of a specific 'Voting Rights Disclosure' code, 'RNS' (Regulatory Filings - general fallback) is appropriate, although 'SHA' is a possibility if the intent is to capture all capital structure data. Since it is a mandatory disclosure of the total count as of a specific date, and not a transaction (POS) or a change announcement (SHA), RNS is the safest general regulatory classification. However, the content is highly specific to the capital structure count. Let's re-evaluate the options. It is not a dividend (DIV), not a director dealing (DIRS), and not a major shareholding change (MRQ). It is a formal publication of the total share count. In many jurisdictions, this is a specific periodic filing. Given the options, and its nature as a mandatory regulatory disclosure about the capital base, RNS is the most appropriate fallback for this specific type of periodic capital structure update that isn't a transaction or a change event.
2022-04-04 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.